August #50 : More on the Nuke-Lipo Link - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Bug Bugaboo

The Universe, Concealed

The Curious Closets of Barton Benes

Trailblazer

Net Serve

Catching Up With...

S.O.S

To the Editor

Court to Mom: “Don’t Milk It”

HIV Tat Spat

Livin' la Vida Loca

Heaven’s Gates

Say What

No Sharp Shooter

Squibb’s Dibs

Tooth Fairy

Meds Downed in Lockup

Coming Attraction

POZ Picks

Enigma of the People

Thymus of the Essence

The AIDS-Friendly HMO

Someone's in the kitchen with...

Thorne on Our Side

Obits

The Bully

A Spy in the House of Love

Is the Crisis Over?

Get Over It

More on the Nuke-Lipo Link

Viagra, Poppers and...

60 Years!?!

Toot the Hormone

Penny Pincher

Smear Campaign

Loading Zone

See Emily Play

Shagalicious Shaw



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

August 1999

More on the Nuke-Lipo Link

by Lark Lands

As soon as lipodystrophy began unleashing its menagerie of humps, lumps and bumps, certain researchers disputed the widespread assumption that this fat redistribution was caused solely by protease inhibitors (PIs). Now Spanish scientists have found marked differences in the incidence of the syndrome relating to a different drug class—nucleoside analogs. More than 40 percent of the 150 HAART-takers followed for two years developed lipo symptoms, on average within eight months of beginning their PI/nuke combos. Everyone in the study was on some PI, but the lipo incidence ranged from a low of 2 percent in those also on AZT (Retrovir) with 3TC (Epivir), to 52 percent in those taking d4T (Zerit) with 3TC, to a high of 88 percent in those given ddI (Videx) with d4T. A variety of PIs was used by each group of nuke users, and PI type was not thought to account for the differences.

In another lipo study, Toronto scientists found that one of the most worrisome aspects of the syndrome, elevated triglyceride levels, also varied widely by drugs taken—in this case, the PIs. One third of PI-takers had elevated levels of blood fats, versus only 11 percent of those not on PIs. But the biggest increase was in those taking ritonavir (Norvir) or ritonavir with saquinavir (Invirase), followed by (in descending order): nelfinavir (Viracept), indinavir (Crixivan) and saquinavir alone. What’s truly alarming is that in 11 percent of the people on PIs, triglyceride levels were high enough (above 11 millimoles/liter) to pose a significant risk for pancreatitis, a potentially fatal inflammation of the pancreas.




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    usuallyhappy
    Palm Springs
    California


    pevans
    San Francisco
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.